MedTrace Logo

Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of Invasive Aspergillosis

NCT01176071 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2010-08-05

No results posted yet for this study

Summary

The investigators hypothesize that early galactomannan and beta-D-glucan features, namely the height of the initial value at the time of diagnosis and the subsequent rate of marker decay within the first week(s) following therapy (day 7, day 14) are important factors in predicting clinical outcome.

Conditions

  • Invasive Aspergillosis

Sponsors & Collaborators

  • University Hospital, Gasthuisberg

    lead OTHER

Principal Investigators

  • Johan A Maertens, MD, PhD · UZ Gasthuisberg Leuven

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-12-31
Completion
2011-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01176071 on ClinicalTrials.gov